ReviewDrugs1994
Parenteral aminoglycoside therapy. Selection, administration and monitoring.
Review in Drugs, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 88 citations in OpenAlex.
- Amikacin population pharmacokinetics in critically ill Kuwaiti patients.BioMed research international · 2013Trial
- Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics.World journal of gastroenterology · 2005Trial
- Population pharmacokinetics of netilmicin in short-term prophylactic treatment.British journal of clinical pharmacology · 2003Trial
- Population pharmacokinetics of amikacin in critically ill patients.Antimicrobial agents and chemotherapy · 1996Trial
- A Pre-Set Calcium Sulfate/Hydroxyapatite Biomaterial as an Antibiotic-Eluting Bone Extender and a Carrier for BMP-2: A Pilot Study in a Rabbit Posterolateral Spinal Fusion Model.Journal of functional biomaterials · 2026Article
- Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence and Clinical Characteristics of Mitochondrial DNA Mutations in Korean Patients With Sensorineural Hearing Loss.Journal of Korean medical science · 2023Article
- Activity of fosfomycin and amikacin against fosfomycin-heteroresistantAntimicrobial agents and chemotherapy · 2023Article
- Amikacin Therapy in Japanese Pediatric Patients: Narrative Review.International journal of environmental research and public health · 2022Review
- Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients.Antibiotics (Basel, Switzerland) · 2021Article
- A mechanistic approach to prove the efficacy of combination therapy against New Delhi metallo-β-lactamases producing bacterial strain: a molecular and biochemical approach.European journal of medical research · 2020Article
- Can Aminoglycosides Be Used as a New Treatment forInfection & chemotherapy · 2019Article
- Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.Paediatric drugs · 2018Article
- Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017Article
- Drug-induced acute kidney injury in children.British journal of clinical pharmacology · 2015Review
- Population pharmacokinetics of gentamicin and dosing optimization for infants.Antimicrobial agents and chemotherapy · 2015Article
- Netilmicin-induced carpopedal spasm.Journal of pharmacology & pharmacotherapeutics · 2014Article
- [Antibiotic therapy: impact and resistance].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- A 2011-2012 survey of doctors' perceptions of korean guidelines and empirical treatment of community-acquired pneumonia.Infection & chemotherapy · 2013Article
- Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection.International journal of otolaryngology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extracellular, but penetration into cerebrospinal fluid and other secretions is meagre. They display trough concentration-dependent reversible nephrotoxicity and The commonly irreversible ototoxicity, which may present after treatment ceases. Gentamicin is the usual all-purpose agent of choice, tobramycin is slightly more effective against Pseudomonas aeruginosa infections, amikacin is the least susceptible to degradation by bacterial enzymes and netilmicin is probably the least toxic. Clinical and drug concentration monitoring have a role in therapy. Aminoglycosides exhibit enduring antibacterial activity (especially against Gram-negative bacilli) many hours after tissue concentrations become negligible. Appreciation of this postantibiotic effect is leading to replacement of conventional multiple daily doses by large single daily doses. The latter regimens confer at least equivalent efficacy and less risk of toxicity (particularly renal). However, single daily dosage may be unsuitable for immunocompromised patients and in those with infective endocarditis, where there is insufficient experience. Cotreatment with beta-lactams is commonly used in order to exploit the synergism between these agents, particularly in enterococcal endocarditis and severe Gram-negative sepsis. Liposomal aminoglycosides are promising parenteral formulations. After being taken up by phagocytes they reach the liver, spleen and sites of inflammation; subsequently they are gradually released. To substantiate the applicability of these hitherto experimental formulations, findings from clinical studies are keenly awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.